Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Result of AGM
Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that at the AGM held earlier today, all resolutions were duly passed on a show of hands.
The results of the poxy are set out below:
| Resolution |
| In favour | % | Against | % | Withheld |
| 1 | Ordinary | 3,096,432,946 | 99.87 | 4,000,000 | 0.13 | 859,285 |
| 2 | Ordinary | 3,091,355,706 | 99.71 | 9,104,066 | 0.29 | 832,459 |
| 3 | Ordinary | 3,096,355,706 | 99.87 | 4,104,066 | 0.13 | 832,459 |
| 4 | Ordinary | 3,091,355,706 | 99.71 | 9,104,066 | 0.29 | 832,459 |
| 5 | Ordinary | 3,091,355,706 | 99.71 | 9,104,066 | 0.29 | 832,459 |
| 6 | Ordinary | 3,091,355,706 | 99.71 | 9,104,066 | 0.29 | 832,459 |
| 7 | Ordinary | 3,091,355,706 | 99.71 | 9,104,066 | 0.29 | 832,459 |
| 8 | Ordinary | 3,096,379,267 | 99.87 | 4,080,505 | 0.13 | 832,459 |
| 9 | Ordinary | 3,096,379,267 | 99.87 | 4,080,505 | 0.13 | 832,459 |
| 10 | Ordinary | 3,090,580,199 | 99.68 | 9,826,573 | 0.32 | 885,459 |
| 11 | Special | 3,059,344,373 | 98.68 | 41,062,399 | 1.32 | 885,459 |
| 12 | Special | 3,085,499,489 | 99.49 | 15,789,742 | 0.51 | 3,000 |
NB: Percentage of Votes case excludes Withheld votes
The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 15 March 2022
For more information:
| Tissue Regenix Group plc David Cocke, Chief Financial Officer | Via Walbrook PR |
|
|
|
| Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Nick Harland | Tel: +44(0)20 7710 7600 |
| Walbrook PR Ltd Alice Woodings / Lianne Applegarth | Tel: +44 (0)20 7933 8780 TissueRegenix@walbrookpr.com |
|
|
|
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs such as in sports medicine, foot and ankle, and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
